Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director · President & CEO | March 16, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
Spyre Therapeutics, Inc.
Report date March 16, 2022 · Filed March 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 550,540 |
Reported balance
After 2022-03-16 transaction · row 1
1 source rowRow 1 · 2022-03-16 · Purchase · Acquired 80,079 · Balance 550,540 F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy trusts | 266,295 |
Reported balance
Holding disclosure · report date 2022-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 266,295 F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date February 09, 2026 · Filed February 09, 2026
Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Other · Disposed 29,928 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | IndirectBy Quinn Family Irrevocable Trust of 2021 | 0 |
Reported balance
After 2026-02-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-09 · Other · Disposed 7,283 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.
F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $33.20 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 8 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | Not disclosed Strike: $48.30 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 7 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,920 | Not disclosed Strike: $61.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 6 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,920 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,500 | Not disclosed Strike: $265.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 5 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 5,200 | Not disclosed Strike: $190.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 3,000 | Not disclosed Strike: $3.87 | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 7,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Quinn Family Irrevocable Trust of 2021 Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3 · ownership.nature: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 17:40 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 29,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 16:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-015958 · form4-06062025_040606.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 16:05 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 85,000 | $0.97 | $82,450.00 |
DisclosureSEC source: 0001415889-25-001417 · form4-01142025_040110.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,286 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.93 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 16:05 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 125,791 | $0.96 | $120,759.36 |
DisclosureSEC source: 0001415889-25-001417 · form4-01142025_040110.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,286 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.92 to $0.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 16:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001415889-24-016184 · form4-06102024_040615.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 16:30 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 88,495 | $1.41 | $124,777.95 |
DisclosureSEC source: 0001415889-23-015857 · form4-12052023_041204.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,495 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:15 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001415889-23-009609 · form4-06122023_040614.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 19,200 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0001415889-22-006475 · form4-06132022_040601.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 06:46 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 80,079 | $2.34 | $187,705.18 |
DisclosureSEC source: 0001209191-22-019929 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,540 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 18:32 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 42,417 | $1.86 | $78,942.28 |
DisclosureSEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,461 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00 per share, inclusive. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 18:32 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 67,472 | $1.93 | $130,220.96 |
DisclosureSEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,044 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.93 per share, inclusive. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 18:32 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 34,777 | $2.06 | $71,779.73 |
DisclosureSEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,572 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.995 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 16:57 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-011724 · doc4.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 20:39 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 10,526 | $3.75 | $39,472.50 |
DisclosureSEC source: 0001209191-21-069350 · doc4.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,795 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.62 to $3.80 per share, inclusive. F2 · balance_after: Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 20:39 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 43,108 | $3.70 | $159,499.60 |
DisclosureSEC source: 0001209191-21-069350 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,269 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · balance_after: Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 16:01 UTC | Generation Bio Co. GBIO · Entity 67174 | GiftCommon Stock | 72,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005028 · form4-10292021_011020.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 72,837 F1 · kind: The reporting person gifted these shares to the Spousal Lifetime Access Trust (the "Trust"). F2 · ownership.nature: The securities are directly held by the Trust. The reporting person is the settlor of the Trust, M. Clare Quinn is the trustee for the Trust and the Trust is for the benefit of Emma, Richard, and Charles Quinn. The reporting person may be deemed to beneficially own the shares of common stock owned by the Trust. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 16:01 UTC | Generation Bio Co. GBIO · Entity 67174 | GiftCommon Stock | 72,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005028 · form4-10292021_011020.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person gifted these shares to the Spousal Lifetime Access Trust (the "Trust"). Read SEC document |
| October 20, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 8 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 208,845 F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee. Read SEC document |
| October 20, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 7 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,795 Read SEC document |
| October 18, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 23,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 6 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 208,845 F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee. Read SEC document |
| October 18, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 23,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 5 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,795 Read SEC document |
| October 14, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 175,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 208,845 F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee. Read SEC document |
| October 14, 2021 Filed Feb 14, 2022 17:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GiftCommon Stock | 175,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,795 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 16:22 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001209191-21-044388 · doc4.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-29 Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 16:08 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $26.59 | $0.00 |
DisclosureSEC source: 0001415889-21-002949 · form4-06112021_010609.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:08 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001209191-21-012424 · doc4.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 16:16 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001209191-20-039724 · doc4.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-30 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:31 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries C Preferred Stock · Derivative | 53,654 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017107 · doc4.xml · derivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,376 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:31 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 30,376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017107 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:23 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016553 · doc4.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| April 30, 2020 Filed May 4, 2020 07:30 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 165,000 | $4.75 | $783,750.00 |
DisclosureSEC source: 0001209191-20-026662 · doc4.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538,469 F1 · balance_after: Includes 788 shares acquired by the Reporting Person on August 15, 2019 and 773 shares acquired by the Reporting Person on February 15, 2020 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 17:13 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 301,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001567619-20-004316 · doc1.xml · derivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,000 Underlying: Common Stock · 301,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 16:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionStock Option (right to buy) · Derivative | 17,603 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001567619-19-019297 · doc1.xml · derivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,914 Underlying: Common Stock · 17,603 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exerciseable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 16:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionStock Option (right to buy) · Derivative | 662 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001567619-19-019297 · doc1.xml · derivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 662 shares Expires 2026-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exerciseable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 16:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 17,603 | $6.31 | $111,074.93 |
DisclosureSEC source: 0001567619-19-019297 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 16:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | Exercise / conversionCommon Stock | 662 | $5.46 | $3,614.52 |
DisclosureSEC source: 0001567619-19-019297 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 17:22 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 5,282 | $6.23 | $32,912.67 |
DisclosureSEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,643 F3 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.18 to $6.2825 per share. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:22 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 14,406 | $6.17 | $88,836.04 |
DisclosureSEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,361 F2 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.23 per share. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:22 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 12,217 | $6.11 | $74,704.51 |
DisclosureSEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,955 F1 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.07 to $6.20 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| May 22, 2019 Filed May 22, 2019 16:55 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 3,809 | $6.86 | $26,128.22 |
DisclosureSEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 3 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,738 F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.69 to $7.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 21, 2019 Filed May 22, 2019 16:55 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 13,794 | $6.89 | $94,981.35 |
DisclosureSEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 2 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,929 F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.53 to $7.00 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 20, 2019 Filed May 22, 2019 16:55 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 8,989 | $6.56 | $58,922.90 |
DisclosureSEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 1 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,135 F1 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.73 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 17, 2019 Filed May 17, 2019 17:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 6,218 | $6.65 | $41,335.40 |
DisclosureSEC source: 0001567619-19-011561 · doc1.xml · nonDerivative · entry 4 Quinn Anthony G. · CIK 0001532219 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,146 F4 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.51 to $6.85 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.